Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.03 -0.65%

-$0.02 today

Market cap
$103.75M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.01M

Average 0.04M

CLLS Common Stock Issued

Cash raised by issuing new shares.

Cellectis S.A.NASDAQ: CLLS

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued outflow grows to $30.11K

Q1 FY2026 common stock issued was $30.11K, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $74.25K.

Context

  • Common stock issued amounted to 0.1% of revenue in FY2025, down 199.1 pp from a year earlier.
  • Common stock issued increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly common stock issued holds near $30.11K or moves back toward the trailing-twelve-month quarterly average of $18.56K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$30.11K-31.8% QoQ
Last fiscal yearDec 2025
$44.14K-99.9% YoY
LTMMar 2026
$74.25K-99.9% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-99.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
44.14K USD
Year-over-year change
-99.9%
4-year CAGR
-82.3%

Common Stock Issued vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -99.9% is the lowest of 8, against a peer median of +27.9%.
  • Common stock issued amounts to 0.1% of revenue for CLLS, versus a peer median of 0.3%.
CLLS Competitors
Common Stock Issued for CLLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DBVTDBV Technologies S.A.LTM Mar 2026$365.24M USD+53690.4%+12.5%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$173.2M USD+62179.2%-4.7%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$165.08M USD+206250.0%+956.5%—
KRROKorro Bio, Inc.LTM Mar 2026$88.73M USD+27.9%+122.7%2309.3%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$45.77M USD—+138.8%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$191.89K USD-82.6%-2.7%—
AMRNAmarin Corporation plcLTM Mar 2026$140.33K USD+15.9%-40.5%0.1%
CLLSCellectis S.A.LTM Mar 2026$74.25K USD-99.9%—0.1%
MREOMereo BioPharma Group plcLTM Mar 2026$38.73K USD——7.7%
ACIUAC Immune S.A.LTM Dec 2025CHF 11.02K CHF-90.1%-6.5%0.3%
SLNSilence Therapeutics plcLTM Mar 2026$911.01 USD—-93.4%0.1%
Peer median (excluding CLLS) —+27.9%-2.7%0.3%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(96.75M)(98.69M)(116.84M)(36.7M)(67.8M)
Depreciation & Amortization14.16M18.44M18.52M19.84M20.12M
Deferred Income Tax087K371K00
Stock-Based Compensation11.49M6.04M5.23M00
Change in Working Capital(12.3M)(5.72M)(3.99M)53.57M(41.72M)
Accounts Receivables(12.44M)(8.99M)2.25M(6.72M)(4.44M)
Inventory215K0000
Accounts Payables177K3.25M(6.31M)2.05M(3.27M)
Other Working Capital(252K)23K67K58.24M(34.01M)
Other Non-Cash Items(21.17M)(7.6M)71.95M(14.61M)49.26M
Operating Cash Flow(104.56M)(87.44M)(24.75M)22.1M(40.14M)
Capital Expenditures(18.56M)(2.44M)(1.07M)(2.58M)(2.37M)
Acquisitions (Net)00000
Purchases of Investments(143K)00(162.48M)(160.27M)
Sales of Investments15M126K063.69M134.24M
Other Investing Activities10.97M(456K)(14.44M)00
Investing Cash Flow7.28M(2.76M)(15.51M)(102.63M)(29.58M)
Debt Repayment(10.64M)(6.6M)24.56M18.17M(5.4M)
Common Stock Issued44.64M067.94M82.68M44.14K
Common Stock Repurchased0(569K)000
Dividends Paid00000
Other Financing Activities13.53M8.32M(9.64M)(11.04M)(10.85M)
Financing Cash Flow47.53M1.15M82.87M89.8M(16.2M)
Effect of Forex Changes(5.75M)(3.36M)884K(2.73M)6.24M
Net Change in Cash(55.51M)(92.42M)43.49M6.54M(79.67M)
Free Cash Flow(123.12M)(89.89M)(25.82M)19.52M(42.5M)

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.